BLS & Co. has served as location and incentives advisor to Roche, Swiss multinational healthcare company, and its subsidiary Genentech, the South San Francisco-based biotechnology industry leader. Our engagements with Roche date back to 2012 with three major projects announced as of 2026:

• North Carolina - During our most recent engagements supporting Genentech, BLS & Co. managed a nationwide search for a new drug product manufacturing facility. BLS managed a nationwide site evaluation and incentives strategy leading to a site in Holly Springs, North Carolina to be selected – the company’s first in the Eastern U.S. The facility will invest a total of $2 billion and create 520 jobs.
• Oregon - In 2018, BLS & Co. also supported Genentech’s selection of an office in the Lloyd District of Portland, Oregon, as a second location for its Access Solutions Patient Service Center, employing approximately 300 full-time specialists during the peak insurance benefit open season.
• New York – Our first assignment for Roche required support for a fast-track decision on the relocation of high-priority R&D operations, also facilitating its planned exit and redevelopment of a legacy site.  Roche engaged BLS to assist with site selection and incentives negotiations of the TCRC eventually led to the company selecting the East River Science Park on Manhattan’s east side.  

• Over $2 billion in planned investment
• 1,000+ full-time jobs